Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Nov 5;32(2):159-167.
doi: 10.1515/revneuro-2020-0083. Print 2021 Feb 23.

Genetic parkinsonisms and cancer: a systematic review and meta-analysis

Andrea Sturchio  1 , Alok K Dwivedi  2 , Joaquin A Vizcarra  1   3 , Martina Chirra  4 , Elizabeth G Keeling  1 , Ignacio F Mata  5 , Marcelo A Kauffman  6 , Manoj K Pandey  7 , Giandomenico Roviello  8 , Cristoforo Comi  9 , Maurizio Versino  10 , Luca Marsili  1 , Alberto J Espay  1
Affiliations
Meta-Analysis

Genetic parkinsonisms and cancer: a systematic review and meta-analysis

Andrea Sturchio et al. Rev Neurosci. .

Abstract

Genes associated with parkinsonism may also be implicated in carcinogenesis, but their interplay remains unclear. We systematically reviewed studies (PubMed 1967-2019) reporting gene variants associated with both parkinsonism and cancer. Somatic variants were examined in cancer samples, whereas germline variants were examined in cancer patients with both symptomatic and asymptomatic (carriers) genetic parkinsonisms. Pooled proportions were calculated with random-effects meta-analyses. Out of 9,967 eligible articles, 60 were included. Of the 28 genetic variants associated with parkinsonism, six were also associated with cancer. In cancer samples, SNCA was predominantly associated with gastrointestinal cancers, UCHL1 with breast cancer, and PRKN with head-and-neck cancers. In asymptomatic carriers, LRRK2 was predominantly associated with gastrointestinal and prostate cancers, PRKN with prostate and genitourinary tract cancers, GBA with sarcoma, and 22q11.2 deletion with leukemia. In symptomatic genetic parkinsonism, LRRK2 was associated with nonmelanoma skin cancers and breast cancers, and PRKN with head-and-neck cancers. Cancer was more often manifested in genetic parkinsonisms compared to asymptomatic carriers. These results suggest that intraindividual genetic contributions may modify the co-occurrence of cancer and neurodegeneration.

Keywords: LRRK2; cancer; genetic parkinsonism; meta-analysis; systematic review.

PubMed Disclaimer

References

    1. Agalliu, I., Ortega, R.A., Luciano, M.S., Mirelman, A., Pont-Sunyer, C., Brockmann, K., Vilas, D., Tolosa, E., Berg, D., Warø, B., et al. (2019). Cancer outcomes among Parkinson’s disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson’s disease patients, and nonaffected controls. Mov. Disord. 34: 1392–1398, https://doi.org/10.1002/mds.27807.
    1. Araki, M., Ito, G., and Tomita, T. (2018). Physiological and pathological functions of LRRK2: implications from substrate proteins. Neuronal Signaling 2: NS20180005, https://doi.org/10.1042/ns20180005.
    1. Atashrazm, F. and Dzamko, N. (2016). LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives. J. Clin. Pharmacol. 8: 177–189, https://doi.org/10.2147/cpaa.s102191.
    1. Bajaj, A., Driver, J.A., and Schernhammer, E.S. (2010). Cancer Causes Control 21: 697, https://doi.org/10.1007/s10552-009-9497-6.
    1. Becker, C., Brobert, G.P., Johansson, S., Jick, S.S., and Meier, C.R. (2010). Cancer risk in association with Parkinson disease: a population-based study. Park. Relat. Disord. 16: 186–190, https://doi.org/10.1016/j.parkreldis.2009.11.005.

LinkOut - more resources